Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record HighInvestors Business Daily • 05/16/23
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)PRNewsWire • 05/16/23
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move TodayThe Motley Fool • 05/01/23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 04/26/23
Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023PRNewsWire • 04/20/23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 04/03/23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common StockPRNewsWire • 03/30/23
Viking Therapeutics Steps Into The Obesity Ring — And Catapults 63%Investors Business Daily • 03/28/23
Viking Therapeutics shares up more than 50% on positive trial results for obesity drugProactive Investors • 03/28/23